Abstract library

97 results for "natural course".
#664 Natural Course and Survival of Thymic and Bronchopulmonary Neuroendocrine Tumors are Different for Male and Female MEN-1 Patients
Introduction: The course of thymic- and bronchopulmonary neuroendocrine tumors (Th- and Bp-NET) in MEN-1 patients is still unclear.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Joanne De Laat
#806 Long-Term Prognosis of Pancreatic Neuroendocrine Tumors in Von Hippel-Lindau Disease
Introduction: Management of pancreatic neuroendocrine tumours (PNET) associated with von Hippel-Lindau (VHL) disease is challenging because of their malignant potential and poorly predictable prognosis.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Louis De Mestier
#1017 The Natural History of an Apparently Aggressive Gastric Neuroendocrine Neoplasm Type 1
Introduction: Gastric neuroendocrine neoplasm type 1 (GNEN1) is the most common GEP-NETs. GNEN1 has traditionally been considered non-metastatic as compared to the large, solitary GNEN3 that has high malignant potential.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Dr Krystallenia Alexandraki
Keywords: GNEN1
#957 Outcome Predictors of Gastrinomas: The Role of ENETS Staging, Grading and Interdisciplinary Treatment
Introduction: Gastrinomas are rare neuroendocrine neoplasias (NEN) presenting with Zollinger‐Ellison‐syndrome (ZES).
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: M.A. Stephan Felder
Authors: Felder S, Jann H, Tischer E, Pascher A, ...
#1317 Value of Octreoscan and 18FDG-PET for Clinical Prognosis of Patients with Neuroendocrine Neoplasms
Introduction: Despite the existence of biological markers of aggressiveness, the clinical course of gastro-entero-pancreatic (GEP) neuroendocrine neoplasms (NEN) remains difficult to predict. Discrepancies between imaging data generated with 111In-pentetreotide scintigraphy (SRS) and 18 F-FDG-PET could reflect the degree of cellular de-differentiation.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Professor Francois Pralong
Authors: Gouffon M, Prior J, Ratib O, Krause T, ...
#824 Metachronous Functioning Syndromes in Sporadic Pancreatic Neuroendocrine Tumors (PNET)
Introduction: A metachronous functioning syndrome (MFS) may develop during the evolution of PNET initially functioning or not.
Conference: 11th Annual ENETS Conference (2014)
Category: Clinical cases/reports
Presenting Author: Louis De Mestier
Authors: De Mestier L, Hentic O, Cros J, Brixi H, ...
#749 Natural History of Atypical Carcinoid of Lung After Surgery
Introduction: The natural history of atypical carcinoid (AC) is poorly known.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Francesca Marciello
#751 Natural History of Resectable Large Cell Neuroendocrine Carcinoma of the Lung
Introduction: Lung large cell neuroendocrine carcinomas (LCNEC) are rare poorly differentiated carcinoma. Their natural history after surgery has been seldom studied.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Francesca Marciello
#1890 Natural History of Type 1 Gastric Carcinoid (gNENs) and Risk of Adenoma/Adenocarcinoma in Endoscopic Surveillance Programme
Introduction: Patients with gNENs & autoimmune gastritis are exposed to 2 malignant risks: 1)transformation of gNENs, felt to be low & guidelines advocate either resection of all lesions or selective endoscopic mucosal resection(EMR) of larger lesions; 2)ill-defined risk of gastric adenoma/adenocarcinoma.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD, MRCPI, MRCP Jun Liong Chin
Keywords: Type 1 g-NENs
#80 Metastatic growth hormone secreting pituitary carcinoma treated with peptide receptor radionuclide therapy
Introduction: Pituitary carcinoma (PC) is an extremely rare condition defined by the presence of adenohypophyseal neoplastic tissue outside the pituitary. Clinical experience regarding diagnosis, management and prognosis of PC is very limited. Growth hormone (GH) secreting PC is even rarer and represents a particular challenge to clinical practice. Therapeutic modalities utilized to treat PC include surgery, radiation, hormonal therapy, and cytotoxic drugs. Peptide Receptor Radionuclide Therapy (PRRT) is an emerging therapeutic modality that involves the targeted delivery of an ablative dose of radiolabelled somatostatin analog. PRRT has been applied to various neuroendocrine tumors and results in prolonged survival and enhanced quality of life. As yet, this therapy has not been applied to malignant pituitary tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Sameer Kassem